{"id":"NCT01966471","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","officialTitle":"A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-31","primaryCompletion":"2019-11-27","completion":"2021-06-04","firstPosted":"2013-10-21","resultsPosted":"2021-01-12","lastUpdate":"2022-06-14"},"enrollment":1846,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab Emtansine","otherNames":["Kadcyla"]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin"]},{"type":"DRUG","name":"Pertuzumab","otherNames":["Perjeta"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Epirubicin","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"5-Fluorouracil","otherNames":[]}],"arms":[{"label":"Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane","type":"ACTIVE_COMPARATOR"},{"label":"Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab","type":"EXPERIMENTAL"}],"summary":"This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg) and pertuzumab at a dose of 420 milligrams (mg) intravenously (IV) every 3 weeks (q3w) or trastuzumab at a dose of 6 mg/kg and pertuzumab at a dose of 420 mg IV q3w in combination with a taxane.","primaryOutcome":{"measure":"Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation","timeFrame":"Last participant randomized to data cut-off date of 27 November 2019 (approximately 70 months). The 3 year IDFS event-free rate was assessed based on the data collected for each participant considering the cut-off date mentioned above.","effectByArm":[{"arm":"Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane","deltaMin":94.1,"sd":null},{"arm":"Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab","deltaMin":92.75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8270"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":15},"locations":{"siteCount":295,"countries":["United States","Australia","Belgium","Bosnia and Herzegovina","Brazil","Canada","Chile","Colombia","Czechia","El Salvador","France","Georgia","Germany","Guatemala","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","Norway","Panama","Peru","Philippines","Poland","Romania","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["34890214"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":216,"n":926},"commonTop":["Alopecia","Nausea","Diarrhoea","Fatigue","Constipation"]}}